Merck's Gefapixant CRL Dashes Hopes For Another Near-Term Growth Driver

 
• By Jessica Merrill
  
rejection
Merck received a CRL from FDA • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip